ClinicalSafetyProfileOTCOmeprazoleMagnesium(Prilosec.ppt

Clinical Safety ProfileOTC Omeprazole Magnesium (Prilosec 1TM) ;Safety Profile Issues;Outline of Talk;Outline of Talk (Cont.);Adverse Events - Short-term Exposure4 Databases;OTC Trials (n=8,179);OTC Omeprazole Side-effects;Short Term Toxicity;Liver Injury;Hepatitis Incidence;Liver Toxicity Post-Marketing;Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome;White Blood Cell SuppressionIncidence;White Blood Cell Suppression SafeTNet;Hypersensitivity ;Hypersensitivity (SafeTNet) Serious Adverse Events ;Hypersensitivity;Swedish Post-Marketing 1998-1999 Voluntary Reporting;Swedish Post-Marketing 1998-1999  Summary;Effects on Drug Clearance;Drug-Drug Interactions;Adolescents;Safety in Adolescents;Embryo-Fetal Damage;Adverse Events - Long-Term Exposure;Concern on Long-Term OTC Use;Masking of Gastric Malignancy;GERD Complications ;GERD Complications;GERD: Standard of Medical Care*;GERD: Standard of Medical Care*;GERD Management Summary;GERD Management;Is Omeprazole Tumorigenic in Humans?;Omeprazole Induced Hypergastrinemia;Omeprazole Induced Hypergastrinemia;Genotoxicity;GenotoxicitySummary;Difficulties in Determining Carcinogenicity of Omeprazole;Difficulties in Determining Carcinogenicity of Omeprazole;Evidence to Date of CarcinogenicitySummary of Clinical Studies, SafeTNet and Literature;Rebound of Gastric Acid Secretion;Rebound of Gastric Acid Secretion;Summary of Safety Issues;Summary of Safety Issues;Summary of Safety Issues;Summary of Safety Issues ;Summary of Safety Issues;Summary of Safety Issues Long-term use ;Summary of Safety Issues Long-term use;Safety:Risk Management;Safety:Risk Management;